Roche Ends Obesity Development of Emugrobart, a Muscle-Preserving Anti-Myostatin Antibody, After Phase 2 GYMINDA Interim Analysis
Chugai announced on Monday, September 28, 2026 that Roche is discontinuing development of emugrobart (GYM329), a subcutaneous anti-latent myostatin antibody, for obesity after an interim analysis of the Phase 2 GYMINDA study concluded that the trial was unlikely to meet its pre-specified weight-loss objectives. GYMINDA tested emugrobart in combination with GLP-1/GIP receptor agonists in people with obesity or overweight; Chugai said the antibody was well tolerated, with no new safety signals. All rights return to Chugai, which is preparing to resume development in spinal muscular atrophy and considering out-licensing; Roche had already stopped emugrobart development in spinal muscular atrophy and facioscapulohumeral muscular dystrophy in March 2026.